Puhalla, S., Wilks, S., Brufsky, A. M., O’Shaughnessy, J., Schwartzberg, L. S., Berrak, E., . . . Vahdat, L. (2016). Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as first-line treatment for human epidermal growth factor receptor 2 positive locally recurrent or metastatic breast cancer: Results from a Phase II, single-arm, multicenter study. Breast Cancer (Dove Med Press).

Puhalla, Shannon, Sharon Wilks, Adam M. Brufsky, Joyce O’Shaughnessy, Lee S. Schwartzberg, Erhan Berrak, James Song, and Linda Vahdat. "Clinical Effects of Prior Trastuzumab On Combination Eribulin Mesylate Plus Trastuzumab As First-line Treatment for Human Epidermal Growth Factor Receptor 2 Positive Locally Recurrent or Metastatic Breast Cancer: Results From a Phase II, Single-arm, Multicenter Study." Breast Cancer (Dove Med Press) 2016.

Puhalla, Shannon, et al. "Clinical Effects of Prior Trastuzumab On Combination Eribulin Mesylate Plus Trastuzumab As First-line Treatment for Human Epidermal Growth Factor Receptor 2 Positive Locally Recurrent or Metastatic Breast Cancer: Results From a Phase II, Single-arm, Multicenter Study." Breast Cancer (Dove Med Press) 2016.